$JRSS
JRSIS HEALTH CARE Corp

2022 Q3 Form 10-Q Financial Statement

#000121390022056091 Filed on September 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $15.62M
YoY Change 113.2%
Cost Of Revenue $3.331M
YoY Change 146.52%
Gross Profit $12.29M
YoY Change 105.66%
Gross Profit Margin 78.67%
Selling, General & Admin $125.4K $100.4K $3.730M
YoY Change -96.58% -97.09% 46.06%
% of Gross Profit 30.35%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.166K $1.505K $882.2K
YoY Change -99.74% -99.81% 9.19%
% of Gross Profit 7.18%
Operating Expenses $132.5K $127.3K $8.308M
YoY Change -98.41% -98.31% 66.92%
Operating Profit -$132.5K -$127.3K $3.980M
YoY Change -112.28% -106.8% 298.93%
Interest Expense -$406.5K
YoY Change 39.46%
% of Operating Profit -10.21%
Other Income/Expense, Net $981.9K -$6.750K
YoY Change -3090.73% 78.57%
Pretax Income -$132.5K -$127.3K $3.567M
YoY Change -118.05% -109.09% 407.78%
Income Tax $928.4K
% Of Pretax Income 26.03%
Net Earnings -$132.5K -$127.3K $1.847M
YoY Change -135.94% -119.1% 463.71%
Net Earnings / Revenue 11.83%
Basic Earnings Per Share $0.00 -$0.82 $0.14
Diluted Earnings Per Share $0.00 -$0.82 $98.05K
COMMON SHARES
Basic Shares Outstanding 58.37M shares 43.87M shares 18.63M shares
Diluted Shares Outstanding 58.37M shares 43.87M shares 18.84M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.08K $37.66K $1.947M
YoY Change -97.9% -87.96% 382.25%
Cash & Equivalents $11.08K $37.66K $1.947M
Short-Term Investments
Other Short-Term Assets $818.2K $900.0K $4.613M
YoY Change -65.84% -72.77% 167.36%
Inventory $1.745M
Prepaid Expenses
Receivables $8.434M
Other Receivables $3.037K $3.219K $415.4K
Total Short-Term Assets $832.3K $954.6K $17.15M
YoY Change -93.15% -90.49% 92.03%
LONG-TERM ASSETS
Property, Plant & Equipment $39.94K $44.52K $60.98M
YoY Change -99.93% -99.91% 20.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.035M
YoY Change 2.7%
Total Long-Term Assets $61.49K $71.49K $64.01M
YoY Change -99.9% -99.87% 19.96%
TOTAL ASSETS
Total Short-Term Assets $832.3K $954.6K $17.15M
Total Long-Term Assets $61.49K $71.49K $64.01M
Total Assets $893.8K $1.026M $81.16M
YoY Change -98.74% -98.43% 30.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.000K $8.000K $14.37M
YoY Change -99.93% -99.91% 84.21%
Accrued Expenses $17.53K $18.37K $1.854M
YoY Change -99.2% -99.14% 87.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $630.6K
YoY Change -100.0% -100.0% 3.37%
Long-Term Debt Due $1.905M
YoY Change -15.02%
Total Short-Term Liabilities $27.53K $26.37K $20.28M
YoY Change -99.84% -99.82% 65.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $15.27M
YoY Change -100.0% -100.0% 4.04%
Other Long-Term Liabilities $5.520K $10.18K $5.394M
YoY Change -99.79% -99.65% 81.92%
Total Long-Term Liabilities $5.520K $10.18K $20.66M
YoY Change -99.97% -99.94% 17.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.53K $26.37K $20.28M
Total Long-Term Liabilities $5.520K $10.18K $20.66M
Total Liabilities $33.05K $36.55K $57.10M
YoY Change -99.93% -99.92% 32.86%
SHAREHOLDERS EQUITY
Retained Earnings -$23.66M -$23.53M
YoY Change
Common Stock $58.37K $58.37K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $860.8K $989.5K $24.06M
YoY Change
Total Liabilities & Shareholders Equity $893.8K $1.026M $81.16M
YoY Change -98.74% -98.43% 30.3%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$132.5K -$127.3K $1.847M
YoY Change -135.94% -119.1% 463.71%
Depreciation, Depletion And Amortization $2.166K $1.505K $882.2K
YoY Change -99.74% -99.81% 9.19%
Cash From Operating Activities $867.3K -$2.486M $4.618M
YoY Change -76.93% -174.15% 1628.95%
INVESTING ACTIVITIES
Capital Expenditures -$1.850K $1.090M -$1.135M
YoY Change -99.93% -353.88% 389.17%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$1.135M -$1.648M
YoY Change -100.0% -17.23% 2469.52%
Cash From Investing Activities -$1.850K -$44.52K -$2.783M
YoY Change -99.96% -97.53% 839.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -900.0K 1.029M -867.5K
YoY Change -220.82% -164.14% 116.74%
NET CHANGE
Cash From Operating Activities 867.3K -2.486M 4.618M
Cash From Investing Activities -1.850K -44.52K -2.783M
Cash From Financing Activities -900.0K 1.029M -867.5K
Net Change In Cash -34.59K -1.501M 967.3K
YoY Change -122.14% 2736.43% -325.35%
FREE CASH FLOW
Cash From Operating Activities $867.3K -$2.486M $4.618M
Capital Expenditures -$1.850K $1.090M -$1.135M
Free Cash Flow $869.2K -$3.576M $5.753M
YoY Change -86.78% -194.56% 1052.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56013
dei Entity Registrant Name
EntityRegistrantName
JRSIS HEALTH CARE CORPORATION.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4562047
dei Entity Address Address Line1
EntityAddressAddressLine1
3/F Building A
dei Entity Address Address Line2
EntityAddressAddressLine2
De Run YuanNo. 19 Chang Yi Road
dei Entity Address Address Line3
EntityAddressAddressLine3
Chang Yi Road, Chang Ming ShuiWu Gui Shan
dei Entity Address City Or Town
EntityAddressCityOrTown
Zhong Shan City
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
528458
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58366569 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37659 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29847 usd
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3219 usd
CY2022Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
13649 usd
CY2022Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
900036 usd
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
13836084 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
954563 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
13865931 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44518 usd
CY2022Q2 jrss Right Of Use Asset Net Noncurrent
RightOfUseAssetNetNoncurrent
26970 usd
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
61826821 usd
CY2022Q2 us-gaap Assets
Assets
1026051 usd
CY2021Q4 us-gaap Assets
Assets
75692752 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
66000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1456919 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1583 usd
CY2022Q2 jrss Capital Lease Obligations Current Portion
CapitalLeaseObligationsCurrentPortion
16790 usd
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
16076570 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
26373 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17599502 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
7 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
10180 usd
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
24991063 usd
CY2022Q2 us-gaap Liabilities
Liabilities
36553 usd
CY2021Q4 us-gaap Liabilities
Liabilities
42590572 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58366569 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58366569 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18628569 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18628569 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
58366 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
18628 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24452501 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23381121 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23527725 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1877296 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6356 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
545449 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
989498 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22067902 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
11034278 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
989498 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33102180 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1026051 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75692752 usd
CY2022Q2 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
4421 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
4421 usd
CY2022Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81822 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81822 usd
CY2022Q2 us-gaap Supplies Expense
SuppliesExpense
25430 usd
CY2021Q2 us-gaap Supplies Expense
SuppliesExpense
4096 usd
us-gaap Supplies Expense
SuppliesExpense
39756 usd
us-gaap Supplies Expense
SuppliesExpense
5192 usd
CY2022Q2 jrss Rentals And Leases
RentalsAndLeases
6112 usd
jrss Rentals And Leases
RentalsAndLeases
6112 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
8000 usd
CY2021Q2 us-gaap Professional Fees
ProfessionalFees
11237 usd
us-gaap Professional Fees
ProfessionalFees
16000 usd
us-gaap Professional Fees
ProfessionalFees
20145 usd
CY2021Q2 jrss Warrant Expense
WarrantExpense
-13818 usd
jrss Warrant Expense
WarrantExpense
-7 usd
jrss Warrant Expense
WarrantExpense
6713 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1505 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1505 usd
CY2022Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
127290 usd
CY2021Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1515 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
149609 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
32050 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-127290 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1515 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-149609 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-32050 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-127290 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1515 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-149609 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32050 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-127290 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1515 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-149609 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-32050 usd
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-36054805 usd
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1024602 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1551059 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-36182095 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
1023087 usd
us-gaap Profit Loss
ProfitLoss
-33543279 usd
us-gaap Profit Loss
ProfitLoss
1519009 usd
CY2022Q2 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-6356 usd
CY2021Q2 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-2688 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-17557 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-44872 usd
CY2022Q2 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-104913 usd
CY2021Q2 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-469167 usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-301922 usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-353234 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-36070826 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1494942 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33223800 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1917115 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0029
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0001
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0048
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0018
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0029
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0001
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0048
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0017
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.8218
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.056
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.0686
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.0849
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.8218
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.0554
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.0686
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.0839
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8247
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.0559
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.0734
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.0831
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8247
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.0553
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.0734
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.0822
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43872480 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18297296 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31250525 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18271814 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43872480 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18507296 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31250525 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18481814 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28840425 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
495922 usd
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-73749 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29262598 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1023087 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
141428 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
471855 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
30898968 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33102180 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
2638816 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
208210 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35949206 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-34984724 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-127290 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1056510 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
60000 usd
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-970560 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6356 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
989498 usd
us-gaap Profit Loss
ProfitLoss
-33543279 usd
us-gaap Profit Loss
ProfitLoss
1519009 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1551059 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-149609 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-32050 usd
us-gaap Depreciation
Depreciation
1505 usd
jrss Warrant Expenses
WarrantExpenses
-7 usd
jrss Warrant Expenses
WarrantExpenses
6713 usd
us-gaap Share Based Compensation
ShareBasedCompensation
81822 usd
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
900036 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3219 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-62000 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
87171 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1583 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1025961 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-166 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
3157978 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
3619454 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2132017 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3619288 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44518 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-44518 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-2783041 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-2096489 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2827559 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2096489 usd
jrss Noncash Issuance Of Common Stock
NoncashIssuanceOfCommonStock
969296 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60000 usd
jrss Derivative Financial Instrument
DerivativeFinancialInstrument
-7 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1029303 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-867508 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-2004971 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161795 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2004971 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-284565 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-49884 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-818312 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-532056 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
855971 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
844827 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37659 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
312771 usd
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
37659 usd
CY2021Q2 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
30885 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
281886 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
37659 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
312771 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
13086 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
5016 usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
406544 usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
732170 usd
jrss Shares Issued For Officer Compensation
SharesIssuedForOfficerCompensation
-1056510 usd
us-gaap Stock Issued1
StockIssued1
970560 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>C. Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
CY2022Q2 us-gaap Other Expenses
OtherExpenses
981858 usd
CY2022Q2 jrss Expense Term Year
ExpenseTermYear
P3Y
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>E. Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For six months ended June 30, 2022 and 2021, no customer accounted for more than 10% of net revenue. As of June 30, 2022 and December 31, 2021, no customer accounted for more than 5% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
81822 usd
jrss Summary Of Changes In Warrant Liability Table Textblock
SummaryOfChangesInWarrantLiabilityTableTextblock
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Balance at January 1, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Balance at June 30, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022Q2 jrss Negotiated Value
NegotiatedValue
1056510 usd
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.25 pure
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>O. Reclassification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The comparative figures before April 1, 2022 have been reclassified to conform to current year presentation to reflect the disposal of a component of business derived from the recognition of a spin-off transaction on April 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.70 pure
CY2022Q2 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
5392000 shares
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
280523 usd
CY2021Q2 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
280523 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
6122 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
549727 usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
549727 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
45974 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1456 usd
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
44518 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1505 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1505 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1528 usd
CY2022Q1 jrss Lease Payment Term
LeasePaymentTerm
P23M
CY2022Q2 jrss Additional Net Lease Assets
AdditionalNetLeaseAssets
26970 usd
CY2022Q2 jrss Additional Net Lease Liabilities
AdditionalNetLeaseLiabilities
26970 usd
CY2022Q2 jrss Operating Lease Assets
OperatingLeaseAssets
26970 usd
CY2022Q2 jrss Total Lease Assets
TotalLeaseAssets
26970 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16790 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10180 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
26970 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8292 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
17205 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1473 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
26970 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
6112 usd
jrss Lease Asset
LeaseAsset
33082 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
6112 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26970 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33543279 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1519009 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-149609 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-32050 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-33393670 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1551059 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31250525 shares
CY2022Q2 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
13649 usd
CY2022Q2 us-gaap Capital Required For Capital Adequacy
CapitalRequiredForCapitalAdequacy
81822 usd
CY2022Q2 us-gaap Shares Issued
SharesIssued
39130000 shares
CY2022Q2 jrss Acquired Shares
AcquiredShares
8000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18271814 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31250525 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18481814 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.0734
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.0831
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.0734
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.0822
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0048
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0018
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0048
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0017
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.0686
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.0849
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.0686
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.0839
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
usd
CY2022Q1 jrss Owned Percentage
OwnedPercentage
1 pure
CY2022Q2 us-gaap Shares Issued
SharesIssued
39130000 shares
CY2022Q2 jrss Acquired Shares
AcquiredShares
8000000 shares
CY2022Q2 jrss Owned Shares
OwnedShares
47130000 shares
CY2022Q2 jrss Common Stock Percentage
CommonStockPercentage
0.807 pure
CY2022Q1 jrss Total Share Issued
TotalShareIssued
6000000 shares
CY2022Q1 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
60000 usd
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.01
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 jrss Transfer Agreement Description
TransferAgreementDescription
On April 28, 2022, Runteng entered into an agreement regarding a transfer of Harbin Jiarun Hospital Co., Ltd.’s Equity (the “Transfer Agreement”) with Zhang Junsheng. Pursuant to the Transfer Agreement, Runteng transferred to Mr. Zhang equity in Harbin Jiarun Hospital Co., Ltd. (“Jiarun Hospital”) representing 70% of the total equity in Jiarun Hospital and Mr. Zhang transferred to Runteng 5,392,000 shares of the Company’s common stock. On May 27, 2022, the company cancelled 5,392,000 shares of its common stock from Zhang Junsheng. Since this transaction required certain authoritative approval before effective, the publication of these transactions were delay so as to obtain all parties consent and advance authoritative approval. As of May 27, 2022, the issued share balance of the company was 58,366,569, the balance of the number of shares of Mr. Zhang and Mr. Zhong were nil (0%) and 4,7130,000(80.7%), respectively. 
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58366569 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58366569 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18628569 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18628569 shares
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
usd
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
usd
jrss Noncash Issuance Of Common Stock
NoncashIssuanceOfCommonStock
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
jrss Derivative Financial Instrument
DerivativeFinancialInstrument
usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Interest Expense
InterestExpense
usd
jrss Shares Issued For Officer Compensation
SharesIssuedForOfficerCompensation
usd
us-gaap Stock Issued1
StockIssued1
usd
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
usd
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
usd
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
usd
us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
usd
CY2021Q4 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
usd
CY2021Q2 us-gaap Capital Required For Capital Adequacy
CapitalRequiredForCapitalAdequacy
usd
dei Amendment Flag
AmendmentFlag
false
dei City Area Code
CityAreaCode
+86-760-
dei Entity Address Country
EntityAddressCountry
CN
dei Entity Central Index Key
EntityCentralIndexKey
0001597892
dei Local Phone Number
LocalPhoneNumber
88963658

Files In Submission

Name View Source Status
0001213900-22-056091-index-headers.html Edgar Link pending
0001213900-22-056091-index.html Edgar Link pending
0001213900-22-056091.txt Edgar Link pending
0001213900-22-056091-xbrl.zip Edgar Link pending
f10q0622ex31-1_jrsishealth.htm Edgar Link pending
f10q0622ex31-2_jrsishealth.htm Edgar Link pending
f10q0622ex32-1_jrsishealth.htm Edgar Link pending
f10q0622ex32-2_jrsishealth.htm Edgar Link pending
f10q0622_jrsishealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jrss-20220630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
jrss-20220630_lab.xml Edgar Link unprocessable
jrss-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0622_jrsishealth_htm.xml Edgar Link completed
jrss-20220630_pre.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
jrss-20220630_cal.xml Edgar Link unprocessable